Strategic planning in ADC development: insights from Lonza
Drug Target Review
JUNE 2, 2025
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. Each stage must adhere to strict quality and regulatory standards, even before considering fill-finish and packaging.
Let's personalize your content